The influence of estradiol/follicle and estradiol/oocyte ratios on the outcome of controlled ovarian stimulation for in vitro fertilization

References

• Ludwig M, Katalinic A, Diedrich K. Use of GnRH antagonists in ovarian stimulation for assisted reproductive technologies compared to the long protocol. Meta-analysis. Arch Gynecol Obstet 2001; 265: 175–182
   PubMedGoogle Scholar
• Al-Inany H, Aboulghar M. GnRH antagonist in assisted reproduction: a Cochrane review. Hum Reprod 2002; 17: 874–885
   PubMed Web of Science ®Google Scholar
• Daya S. GnRH-agonists versus antagonists in assisted reproduction – a systematic review. Abstract book of the 8th International Symposium on GnRH-analogues in Cancer and Human Reproduction. 2005, A100
   Google Scholar
• Orvieto R, Rabinson J, Meltzer S, Homburg R, Anteby E, Zohav E. GnRH agonist versus GnRH antagonist in ovarian stimulation: is the emperor naked?. Clin Exp Obstet Gynecol 2006; 33: 197–199
   PubMedGoogle Scholar
• Fauser B C, Devroey P. Why is the clinical acceptance of gonadotropin-releasing hormone antagonist cotreatment during ovarian hyperstimulation for in vitro fertilization so slow?. Fertil Steril 2005; 83: 1607–1611
   PubMed Web of Science ®Google Scholar
• Griesinger G, Felberbaum R, Diedrich K. GnRH antagonists in ovarian stimulation: a treatment regimen of clinicians' second choice? Data from the German National IVF Registry. Hum Reprod 2005; 20: 2373–2375
   PubMed Web of Science ®Google Scholar
• Loumaye E, Engrand P, Howles C M, O'Dea L. Assessment of the role of serum luteinizing hormone and estradiol response to follicle-stimulating hormone on in vitro fertilization treatment outcome. Fertil Steril 1997; 67: 889–899
   PubMed Web of Science ®Google Scholar
• Yang J H, Chen H F, Lien Y R, Chen S U, Ho H N, Yang Y S. Elevated E2:oocyte ratio in women undergoing IVF and tubal ET. Correlation with a decrease in the implantation rate. J Reprod Med 2001; 46: 434–438
   PubMed Web of Science ®Google Scholar
• Orvieto R, Bar-Hava I, Yoeli R, Ashkenazi J, Rabinerson D, Bar J, Fisch B. Results of in vitro fertilization in women aged 43–45 years. Gynecol Endocrinol 2004; 18: 75–78
   PubMed Web of Science ®Google Scholar
• Albano C, Felberbaum R E, Smitz J, Riethmuller-Winzen H, Engel J, Diedrich K, Devroey P. Ovarian stimulation with HMG: results of a prospective randomized phase III European study comparing the luteinizing hormone-releasing hormone (LHRH)-antagonist cetrorelix and the LHRH-agonist buserelin. European Cetrorelix Study Group. Hum Reprod 2000; 15: 526–531
   PubMed Web of Science ®Google Scholar
• European Orgalutran Study Group. Treatment with the gonadotrophin releasing hormone antagonist ganirelix in women undergoing ovarian stimulation with recombinant follicle stimulating hormone is effective, safe and convenient: results of a controlled, randomized, multicentre trial. Hum Reprod 2000; 15: 1490–1498
   PubMedGoogle Scholar
• Olivennes F, Belaisch-Allart J, Emperaire J C, Dechaud H, Alvarez S, Moreau L, Nicollet B, Zorn J R, Bouchard P, Frydman R. Prospective, randomized, controlled study of in vitro fertilization–embryo transfer with a single dose of a luteinizing hormone-releasing hormone (LH-RH) antagonist (cetrorelix) or a depot formula of an LH-RH agonist (triptorelin). Fertil Steril 2000; 73: 314–320
   PubMed Web of Science ®Google Scholar
• European-Middle East Orgalutran Study Group. Comparable clinical outcome using the GnRH antagonist ganirelix or a long protocol of the GnRH agonist triptorelin for the prevention of premature LH surges in women undergoing ovarian stimulation. Hum Reprod 2001; 16: 644–651
   PubMedGoogle Scholar
• Fluker M, Grifo J, Leader A, Levy M, Meldrum D, Muasher S J, Rinehart J, Rosenwaks Z, Scott R T, Jr, Schoolcraft W, et al. Efficacy and safety of ganirelix acetate versus leuprolide acetate in women undergoing controlled ovarian hyperstimulation. Fertil Steril 2001; 75: 38–45
   PubMed Web of Science ®Google Scholar
• Fleischer A C, Daniell J F, Rodier J, Lindsay A M, James A E, Jr. Sonographic monitoring of ovarian follicular development. J Clin Ultrasound 1981; 9: 275–280
   PubMedGoogle Scholar
• Tarlatzis B C, Laufer N, DeCherney A H. The use of ovarian ultrasonography in monitoring ovulation induction. J In Vitro Fert Embryo Transf 1984; 1: 226–232
   PubMedGoogle Scholar
• Ben Shlomo I, Geselevich J, Shalev E. Can we abandon routine evaluation of serum estradiol levels during controlled ovarian hyperstimulation for assisted reproduction?. Fertil Steril 2001; 76: 300–303
   PubMedGoogle Scholar
• Orvieto R. Prediction of ovarian hyperstimulation syndrome. Challenging the estradiol mythos. Hum Reprod 2003; 18: 665–667
   PubMed Web of Science ®Google Scholar
• Billig H, Furuta F, Hsueh A IW. Estrogens inhibit and androgens enhance ovarian granulosa cell apoptosis. Endocrinology 1993; 133: 2204–2212
   PubMed Web of Science ®Google Scholar